Lotus Pharmaceuticals ;-)))
| eröffnet am: | 21.01.10 12:48 von: | Kleine_prinz |
| neuester Beitrag: | 11.05.10 17:29 von: | stockplayer |
| Anzahl Beiträge: | 52 | |
| Leser gesamt: | 20210 | |
| davon Heute: | 10 | |
bewertet mit 2 Sternen |
||
|
Seite:
1
|
2
|
||
Lotus Pharmaceuticals, Inc. (LTUS.OB)
Expected next earnings release:
Announcement date: 3/30/2010 - During Market
Earnings Quarter: Q4
Announcement Status: Unconfirmed
http://www.tradingmarkets.com/news/stock-alert/...-notice-751631.html
Kommen werden bestimmt Lotus in neue Dimensionen Katapultieren :-))))))
Lotus ist und bleibt ein volltreffer meine meinung nach ;-)))
We've seen strong performance in many stocks in the market over the last two days. Especially strong have been China stocks which moved sharply higher Tuesday on the heels of healthy trade data and robust economic growth expectations. National Bureau of Statistics Chief Economist Yao Jingyuan said China's economic growth would stay above 8% this year, helping to ally fears of a double-dip recession elsewhere around the globe.
That statement helped to propel many of the China stocks in the Small Cap Investor PRO portfolio sharply higher. And Lotus Pharmaceuticals (OTC BB: LTUS), which I've recommended here in Small Cap Investor Daily, was a top performer,jumping 17% yesterday to close at $1.68.
I've been hammering home one point lately: The market is paying attention to news again. Be sure to remember this, as volatility has increased with investors moving in and out of equities as new news is released. The volatility is creating great buy and sell opportunities for active traders. It's also presenting opportunities for long-term investors looking to pick up shares in companies they've been watching in anticipation of a pullback.
Stock prices will very likely be more volatile this year than in 2009, and we've already seen this with a pullback in January. That means it's going to be even more important to do your research and buy quality stocks at reasonable valuations. It's also going to be crucial for investors to focus on the sectors that will outperform this year. Of course, all of this will be part of our ongoing conversation here in Small Cap Investor Daily.
*** I want to briefly discuss three stocks that readers have sent in to have me take a look at. Now, of course we love to receive requests to look at companies that have glowing prospects and stocks trading at dirt-cheap valuations. Those gems we continue to follow because many of you are buying shares. And it's always exciting to track a company as it grows from a micro-cap, to a small-cap, and eventually to a large-cap stock – making investors huge gains along the way.
But some readers are having a good time finding highly speculative stocks that are not yet profitable, and are sending those in. I don't buy shares of these types of companies, but that doesn't mean you can't trade them for quick gains. I limit risk by investing only in companies that have turned the corner of profitability because, if a company can't earn a return on the products and services it sells, I don't want to invest my hard earned dollars. So buy shares in unprofitable companies if you wish, but be aware that these will be among the first, and fastest, to fall when sellers head for the exits on dismal economic news.
*** So let's take a quick look at some stocks that were recently sent in and I'll point out the red flags that jumped out at me. Consider this the small-cap chopping block. While I usually want to tell you what I like to buy, it's occasionally helpful to take a look at what not to buy too. So for readers who sent these in, don't take this personally. I'm simply trying to cover the spectrum of stocks that readers ask me to look at.
http://www.smallcapinvestor.com/smallcapnews/...n_stock_has_potential
Hierbei sollte mann auch im Auge haben das ein Chinese anders zum Arzt geht als ein Europäer. ein Chinese geht zum Arzt um vorzubeugen, wenn er doch krank wird war der Arzt Kacke. Bei 1,3 Milliarden Chinesen ist der Markt Gigantisch.
Lotus hat eine Marktkapitalisirung von 46Millionen €
http://www.langes-imbiss.com
Hallo, da du hier ja die absolute Threat-Hoheit hast, erklär mir doch mal in knappen Worten warum ich bei Lotus einsteigen soll.
Merci
was erklären muss sorry...
Informiere dich schon selber..
Chinese pharmaceutical stocks are offering great bargains for value investors.
Pharmaceutical sales in China have been growing at an average annual rate of 15.5% since 2005. This growth is being fueled by rising incomes, a growing middle class and a rapidly aging population. The elderly population in China has grown from 171 million from 130 million over the past decade, and health care spending by the elderly is five times higher than it was in 2000.In addition, Beijing has made health care one of its primary initiatives and plans to spend $123 billion on a universal health care in the next three years.
China's pharmaceutical industry is rapidly consolidating, and the market leaders are growing in value.
These leaders have several things in common: a strong nationwide sales and distribution network, strong research and development capabilities and access to capital.
Although some Chinese pharmaceutical companies trade with price-to-earnings ratios as high as 63, Lotus Pharmaceuticals(LTUS.OB Quote) has a P/E of only 5.12.
You would expect a low P/E to be indicative of a stalwart company. However, Lotus Pharmaceuticals grew revenue at 59% from 2005 to 2008, and net income is up 700% since 2005.
The company's revenue comees from a combination of pharmaceuticals wholesaling and the development and sale of proprietary drugs. It plans to continue to grow by expanding distribution channels, expanding production capacity through the building of a large factory and bringing new drugs to the market by partnering with top research institutions.
We believe a company this cheap should not be overlooked. In summary, Lotus is a comprehensive company with both strong manufacturing capability and a nationwide distribution network, great research-and-development capabilities with a new drug pipeline and a very attractive valuation.
http://www.thestreet.com/_yahoo/story/10682144/1/...REE&cm_ite=NA
Ich denke ein wenig Lesen kann doch jeder oder?
Die Lezten news sind alle nicht alt..
Da braucht man eigentlich nur ein wenig zu lesen und man weißt was sache ist..
Es schaut einfach sehr, sehr gut aus ;-))
BEIJING, March 1 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that the Company had adopted a timetable to commence the design phase of its Sarbanes-Oxley Compliance Project in March and enter implementation stage in June, to ensure full and timely Sarbanes-Oxley Act compliance in 2010.
The Company has put together multileveled teams to execute the compliance under the assistance of an independent consultant, Union Strength Business Consulting Co. Ltd., that offers expertise in accounting, finance and internal control.
CEO, Zhongyi Liu, said, "We believe the benefits of successful compliance with the Sarbanes-Oxley Act will not only improve our operational efficiency but also increase shareholders' value."
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.com
http://finance.yahoo.com/news/...prnews-1729387469.html?x=0&.v=92
Lotus Pharmaceuticals Announces New Prescription Drugs
Companies:
BEIJING, March 2 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that it had added five new prescription drugs to its products delivered through its national sales channels.
The five new prescription drugs covered by the National Health Insurance Program are produced by third party manufacturers, have proven its market acceptance and are expected to increase market share substantially. Omeprazole Enteric-coated Capsule is a drug for the treatment of duodenal ulcer. The other four drugs are traditional Chinese medicine in capsules, tablets and ointment respectfully for the treatment of chronic prostate infection, psoriasis, influenza, and meridian pain.
CEO, Zhongyi Liu, said, "The pharmaceutical market is growing at more than 20 percent a year in China according to IMS. We are positioned to capture this opportunity especially the OTC market opportunities as a result of China's reform to separate the functions of prescribing and dispensing."
The Company's product pipeline pending final SFDA approval status includes Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease, Gliclazide-Controlled Release Tablets for Type 2 diabetes and Laevo-Bambutero for asthma. Lotus Pharmaceuticals' products under pre-clinical studies comprise Lovastatin, Verapamil Hydrochloride, and Valsartan-Controlled Release tablets.
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its prior filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
http://finance.yahoo.com/news/...prnews-3908823510.html?x=0&.v=48
Lotus Pharmaceuticals, Inc. Produkte verkündet neue verschreibungspflichtige Medikamente
PEKING, 2. März /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Anschlagbrett: LTUS.ob - Nachrichten) („Lotos“ oder die „Firma“), ein wachsender Entwickler und ein Produzent der verschreibungspflichtigen Medikamente und des genehmigten nationalen Verkäufers der pharmazeutischen Produkte in der Volksrepublik China („PRC“), heute berichtet, dass sie fünf neue verschreibungspflichtige Medikamente seinen Produkten hinzugefügt hatte, lieferten durch seine nationalen Absatzwege.
Die fünf neuen verschreibungspflichtigen Medikamente, die durch das Krankenversicherung-Programm abgedeckt werden, werden durch Drittparteihersteller produziert, haben seine Marktannahme geprüft und werden erwartet, Marktanteil im Wesentlichen zu erhöhen. Omeprazole Enterisch-überzogene Kapsel ist eine Droge für die Behandlung des duodenalen Geschwürs. Die anderen vier Drogen sind traditionelle chinesische Medizin in den Kapseln, Tabletten und Salbe respektvoll für die Behandlung der chronischen Prostatainfektion, der Psoriasis, der Grippe und der Mittagsschmerz.
CEO, Zhongyi Liu, sagte, „der pharmazeutische Markt wächst an mehr als 20 Prozent ein Jahr in China entsprechend IMS. Wir werden in Position gebracht, um diese Gelegenheit besonders die OTC Marktchancen resultierend aus Chinas Verbesserung gefangenzunehmen, die Funktionen des Vorschreibens und des Zuführens zu trennen.“
Der der Produktrohrleitung der Firma Zustimmungsstatus des Schlusses SFDA schwebende umfaßt Isosorbid Mononitrate-Nachhaltige Freigabe-Tabletten für kardiovaskuläre Krankheit, Gliclazide-Kontrollierte Freigabe-Tabletten für Art - Diabetes 2 und Laevo-Bambutero für Asthma. Produkte der Lotos-pharmazeutischen Produkte unter präklinischen Studien enthalten Lovastatin, Verapamil-Hydrochlorid und Valsartan-Kontrollierte Freigabetabletten.
Über Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com)
Lotus Pharmaceuticals, Inc. ist ein wachsender Entwickler und ein Produzent der verschreibungspflichtiger Medikamente und des genehmigten nationalen Verkäufers der pharmazeutischen Einzelteile in der Volksrepublik China. Lotos funktioniert durch seine zwei Steuereinheiten: Der Liang-Reißzahn, der pharmazeutisch sind, Ltd. und en Ze Jia pharmazeutisches Shi, Droge-Entwicklungsrohrleitung der Ltd.-Lotos gegenwärtige wird auf die Behandlung der cerebro-kardiovaskulären Krankheit, des Asthmas und des Diabetes gerichtet. Liang-Reißzahn verkauft Drogen direkt und indirekt durch seine nationalen Absatzwege an Krankenhäuser, Kliniken und Drogespeicher in 30 Provinzen des PRC.
Sicherer Hafen-Aussage
Dieses Pressekommuniqué enthält „vorausschauende Aussagen“ im Sinn von den „Sicherhafen“ Bestimmungen der privaten Sicherheits-Rechtsstreit-Verbesserung-Tat von 1995. Vorausschauende Aussagen umfassen, ohne Beschränkung, jede mögliche Aussage, die zukünftige Resultate, Leistung oder Ausführungen voraussagen, prognostizieren, anzeigen oder andeuten kann, und können die Wörter „Schätzung enthalten,“ „Projekt,“ „Absicht,“ „prognostiziert,“ „vorwegnehmen,“ „Plan,“ „Planung,“ „erwarten,“ „glauben,“ „werden wahrscheinlich,“ „, wenn,“ „,“ „wurden,“ „können,“ oder Wörter oder Ausdrücke der ähnlichen Bedeutung konnten. Solche Aussagen sind nicht Garantien der zukünftigen Leistung und konnten die tatsächlichen Resultate der Firma veranlassen, sich von den Resultaten materiell zu unterscheiden, die ausgedrückt werden, oder angedeutet durch solche Aussagen, einschließlich, aber nicht auf begrenzt, erhöhten Änderungen von vorweggenommenen Niveaus von Verkäufen, zukünftige nationale oder regionale ökonomische und konkurrierende und regelnde Bedingungen, Änderungen in den Verhältnissen zu den Kunden, Zugang zu Haupt, Kosten, Schwierigkeiten in dem Entwickeln und neue Produkte, vermarktende vorhandene Produkte, Kundenwechsel der vorhandenen und neuen Produkte, die Zeit vermarktend, neue Drogen zu erhalten genehmigt durch das Zustand-Behörde zur Überwachung von Nahrungs- und Arzneimitteln und andere Faktoren. Zusätzliche Information betreffend Risiken kann im jährlichen Bericht der Firma über Form 10K und seine vorherigen Archivierungen mit der sek gefunden werden. Dementsprechend obgleich die Firma glaubt, dass die Erwartungen, die in solchen vorausschauenden Aussagen reflektiert werden, angemessen sind, kann es keine Versicherung geben, die solche Erwartungen korrekt sind. Die Firma hat keine Verpflichtung, die vorausschauenden Informationen zu aktualisieren, die in diesem Pressekommuniqué enthalten werden.
Zu mehr Information treten Sie bitte in Verbindung: Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Telefon: +86-10-6389-9868 EMail: zy@lotuspharma.com http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen
YA Global Master SPV Ltd Invests up to US$10,000,000 in Lotus Pharmaceutical, Inc. through Equity Line Facility YA Global Master SPV Ltd¡¯s makes its first Chinese investment for the Year of the Tiger with an investment in the fast growing healthcare sector in China
(Beijing/Hong Kong/New Jersey, March 3, 2010) Lotus Pharmaceutical, Inc. ("Lotus"or the "Company" ), United States OTC Bulletin Board ("LTUS:US"), today announced that it entered into a US$10,000,000 Standby Equity Distribution Agreement ("SEDA") with YA Global Master SPV Ltd ("YA Global"), a fund managed by Yorkville Advisors, LLC of Jersey City, New Jersey USA ("Yorkville"). Yorkville¡¯s Hong Kong office advised on the transaction.
Lotus engages in the production, trade, and retail of pharmaceutical products in the People's Republic of China (PRC), Lotus plans to use the funds for the group¡¯s general corporate and working capital purposes. Lotus currently sells twenty prescription drugs covered by the National Health Insurance Program in the PRC, and four of which are self-produced. The Company operates GMP certified facilities, with direct sales channels to 42 hospitals and a national sales network through 10 regional centres in the PRC.
Dr. Liu Zhong Yi, Chief Executive Officer and Chairman of Lotus said, ¡°We are extremely pleased to welcome Yorkville as a long-term capital partner to Lotus. The partnership will assist our development into a leading player in the growing pharmaceutical market in China. The SEDA allows Lotus, at its discretion, to draw down a total of US$10,000,000 of equity capital in tranches pursuant to the terms of our agreement. This provides additional flexibility to fund our growth strategy,¡± he said.
Anthony Chan, Managing Director and Head of Asia at Yorkville HK said, ¡°We are pleased to become a capital partner to Lotus, which is an emerging leader in the high growth pharmaceutical sector in China. Lotus is based in Beijing and possesses an attractive portfolio of pharmaceutical products which it is licensed to produce and market through its extensive distribution network across China. In addition, the Company has exciting products in the pipeline pending final SFDA approval status and is engaged in the sale of over the counter drugs. The pharmaceutical sector in general is fast growing, on the back of rapid economic development and increasing demand for quality healthcare from the public.¡±
Philip Ho, Senior Managing Director and Head of Global Capital Markets for Yorkville added, ¡°This investment continues our expansion of investments into the Greater China region and extends our focus in the healthcare sector. Our investment in Lotus is indicative of our global investment approach and we look forward to becoming a long term partner and to providing financial support to aid the Company¡¯s expansion strategy.¡±
About Lotus Pharmaceuticals, Inc. ¡¡ Lotus Pharmaceuticals, Inc. engages in the production, trade, and retail of pharmaceuticals in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus¡¯ current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugstores in 30 provinces of the PRC. Its self-produced products include four drugs covered by the National Health Insurance Program: Valsartan for treating hypertension or high blood pressure; Brimonidine Tartrate, a drug used to constrict adrenaline receptors; Nicergoline for Injection, an a-receptor blockage nerve system blood-brain medicine; and Levofloxacin, an anti-bacterial drug for the treatment of mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in conditions, such as acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and acute pyelonephritis, as well as complicated and uncomplicated skin and skin structure infections, and urinary tract infections. The Company¡¯s product pipeline pending final SFDA approval status includes Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease, Gliclazide-Controlled Release Tablets for Type 2 diabetes and Laevo-Bambutero for asthma. Lotus Pharmaceuticals¡¯ products under pre-clinical studies comprise Lovastatin, Verapamil Hydrochloride, and Valsartan-Controlled Release tablets. Lotus is also involved in the retailing of both Western and traditional Chinese medications and medical treatment equipment, research and development, leasing space to various retail merchants and licensed medical practitioners, and the sale of developed drug formulas. It currently operates 10 drug stores in Beijing. ¡¡ About Yorkville Advisors and Yorkville Advisors HK
Founded in January 2001, Yorkville specializes in providing flexible and cost-effective debt and equity financing to publicly listed companies worldwide. Yorkville has a broad investment mandate and the flexibility to invest across many geographies as well as sectors, including healthcare, natural resources, technology media & telecommunication, industrials and shipping.
Yorkville Advisors HK Limited (¡°Yorkville HK¡±), a SFC registered entity, is the Hong Kong-based wholly owned sub-advisor to Yorkville, which is the investment manager to a family of funds.
Yorkville has offices in Jersey City, New Jersey; Jupiter, Florida; Denver, Colorado, London and Hong Kong. It also has joint venture agreements in Italy, Greece and Israel.
~ Ends ~ ¡¡ | |
|---|---|
¡¡ For media enquiries, please contact: Yorkville Advisors: Mr. Joshua Goldman-Brown Kreab Gavin Anderson Phone: +852 2218 9952 Email: jgoldman-brown@kreabgavinanderson.com | ¡¡ For media enquiries, please contact: Lotus Pharmaceuticals Inc: Yan Zeng CFO Phone: +8610 6389 9868 Email: zy@lotuspharma.com |
¡¡ IMPORTANT DISCLOSURES ¡¡ The information contained herein is for informational and discussion purposes only and is not intended to be, nor shall it be, construed as legal, tax or investment advice or as an offer, or the solicitation of any offer, to buy or sell any securities. Before entering into any investment you should thoroughly review the respective transaction documents with your legal, tax and investment advisors. References to Yorkville¡¯s investments consist of opportunities to finance companies in the future. These transactions may or may not be consummated. You should be aware that past performance is not necessarily indicative of future results and an investment involves the risk of loss. Yorkville Advisors HK, Limited (a sub-advisor to Yorkville Advisors, LLC) is, located at 10/F., Jardine House, 1 Connaught Place, Central, Hong Kong and is registered by the Securities and Futures Commission (SFC) in Hong Kong CE No. ASD850.
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words ¡°estimate,¡± ¡°project,¡± ¡°intent,¡± ¡°forecast,¡± ¡°anticipate,¡± ¡°plan,¡± ¡°planning,¡± ¡°expect,¡± ¡°believe,¡± ¡°will likely,¡± ¡°should,¡± ¡°could,¡± ¡°would,¡± ¡°may,¡± or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its prior filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release. ¡¡ |
http://www.lotuspharma.com/Press%20Release2010-03-03.html
BEIJING, March 10 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
Officials of Beijing municipal and Chaoyang district governments, officers of the China State Food & Drug, and representatives of both state-owned and private pharmaceutical companies attended the ceremony.
CEO, Zhongyi Liu, welcomed the guests. "After a year of planning, we are pleased to start the construction of the new building complex and expect to finish the construction by July, interior decoration by September and GMP certification by December of this year," he said. "This is a new page for Lotus' development and it will provide important impetus to profitable growth, which is anticipated to reach $150 million in annual sales during the first year after the facility is fully operational."
The new nine-floor building complex will be used for offices, research and development, production, and modern storage. Until the building complex is complete, interim production of the drugs to be produced at the new facility will be produced by third parties.
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its other filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.com http://finance.yahoo.com/news/...s-Reports-prnews-4078211695.html?x=0
It was a good week for fundings in China life science, with five companies announcing new capital. Chief among them was AutekBio, which released the news that it would take advantage of an impressive $100 million for a biologic CMO facility.
AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing (see story). To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group.
Chongqing Porton Fine Chemicals Co., a CMO, raised $10 million from the Chongqing DT Fund (see story). The Chongqing DT Fund is a joint effort run by DT Capital of Shanghai and funded by the Chongqing Venture Capital Guidance Fund. Porton will use the money to build a state-of-the-art intermediate and API manufacturing facility in Changshou Chemical Park in Chongqing.
TCT Medical Technology, a China medical device company that focuses on the OB/GYN market, has raised $10 million in new capital from two Fidelity funds (see story). TCT claims to be the largest high-tech medical equipment and supplies importer in China within women’s health. It is the exclusive distributor in China of Cytyc’s ThinPrep pap test, the world’s leading cervical cancer screening product.
EA Inc., a company that makes invisible dental braces, completed a $6.6 million Series A financing led by OrbiMed, which provided “nearly all” of the funds, along with individual investors (see story). OrbiMed characterized the financing as a restructuring of EA Inc., which will move its official headquarters to the Cayman Islands, and its operations to Wuxi.
Lotus Pharmaceuticals (LTUS.OB) has begun construction of nine-story building complex that will provide offices, R&D, production, and storage (see story). The new facility is being built on the grounds of its existing production facility in Beijing. Lotus, which has very low levels of cash, did not disclose the facility’s cost or the source of the funds for the project.
There was also some non-funding news in the China life science sphere during the week just past. Xiaochuan Wang, PhD, a returnee who founded Shanghai’s CRO Sundia MediTech in 2004, was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum (see story). From its beginnings in 2004, Sundia has grown to an organization with 400 employees, including more than 300 scientists, which offers CRO services to over 90 customers from the US, Europe and Japan.
As expected, WuXi PharmaTech (NYSE: WX) reported 2009 net revenues of $270 million, an increase of 7% (see story). Net income climbed to $52.9 million, a great improvement from the loss of $64.2 million in 2008, caused in part by a writedown. In 2009, revenues matched analysts’ expectations, while earnings were slightly below forecasts.
Disclosure: none.
http://seekingalpha.com/article/...life-science-fundings?source=yahoo
Chinese Pharmaceuticals by guest blogger, Zack Buckley
March 27, 2010
PART I
When shopping in the supermarket, shoppers always flock to the half off sales. In the stock market, a half off sale creates worldwide panic. Although these circumstances are actually exceptional for long term investors, most people fear the world is ending. I welcome half off sales in the stock market because they are a great way to build long term wealth.
The Chinese pharmaceutical industry presents multiple bargains for value investors. Pharmaceuticals sales in China have been growing at a rate of 15.5% annually from 2005-2010. There is a strong demand for pharmaceutical products in China due to growing income, a larger middle class, and a rapidly aging population. The elderly population in China grew from 130 million in 2000 to 171 million in 2010. Healthcare spending by the elderly is 5 times higher.
In addition the government has made healthcare one of its primary initiatives; as a result, a Universal Health plan package geared to deliver $123 billion in the next three years has been issued.
The industry is rapidly consolidating, where the market leaders are rapidly growing in value. Characteristics of future markets leaders are
1. A strong nationwide sales and distribution network
2. Strong research and development capabilities
3. Access to capital in order to expand
While some companies trade with P/E ratios as high as 63, Lotus pharmaceuticals has a P/E of only 5.12. You would expect a low P/E to be indicative of a stalwart company. However, Lotus Pharmaceuticals grew revenues at 59% from 2005-2008 and has net income up 700% since 2005. Lotus Pharmaceuticals revenue streams are a combination of pharmaceuticals wholesaling and the development and sale of proprietary drugs. Their primary growth strategies are expanding their distribution sales channels in order to increase sales, expanding production capacity through the building of a large factory, and bringing new drugs to the market by partnering with top R&D institutions. We believe a company this cheap should not be overlooked. In summary, lotus is a comprehensive company with both strong manufacturing capability and a nationwide distribution network, great R&D capabilities with a new drug pipeline including a Class I drug, and a very attractive valuation.
China Medicine Corporation (CHME) has a current P/E ratio of 5.91 and P/S of .69. The company is rapidly growing and has developed a proprietary product rADTZ, which is made to decrease animal mortality rates by fighting Aflatoxins, should substantially enhance revenues. They estimate the addressable market for rADTZ is up to $4 billion and that the successful commercialization and licensing of rADTZ has the potential to substantially improve revenue and profit picture in the years to come. Their distribution consists of 300 hospitals and 500 other medical companies, which leads to 2000 drug stores. Revenues are up to 53 million in 2008 from 15 million in 2005. A company like this is extremely cheap. A comparable company is 3sBio, which has a P/E of 22 and a P/S of 3.96. China medicine is much cheaper than 3sBio with better return on equity and profit margins.
China Yongxin CYXN has a current P/E ratio of 4.9 and a P/S ratio of .25. The company has three divisions, they run 93 retail drugstores in China, similar to Walgreens, they are a distributor of pharmaceutical products, and they have their own proprietary ginseng products. The company’s products are Chinese traditional medicines, chemical pharmaceuticals preparations, flower teas, natural health products, healthy food, cosmetics, and medical equipment. CYXN will focus on expanding its retail chain across China. The company has continued to grow its wholesale business and is moving to expand the higher margin retail and manufacturing activities in the pharmaceutical business. Management also plans to eventually uplist, once the company qualifies.
| Symbol | Mkt Cap | P/E | Price/Sales | Rev growth CAGR % 2007-08 | Net income CAGR Growth %, 2007-08 |
| CYXN | 20.20 | 5.00 | .33 | 23% | 13% |
| NPD | 705.60 | 25.00 | 2.00 | 22% | 30% |
| LTUS | 65.58 | 5.12 | .96 | 51% | 11% |
| CHME | 53.93 | 5.91 | 1.00 | 27% | 33% |
| SSRX | 239.94 | 24.03 | .99 | 35% | -23% |
It is clear that these are three great bargains in the Chinese pharmaceuticals industry. I have a hard time believing markets are efficient when I look at these companies. These companies seem to be trading well below their intrinsic values, although I reserve the right to be wrong. In fact, I have founds tons of undervalued Chinese ADRs. That is why I am going to China this summer to visit as many publicly traded companies as I can fit into two and a half months. In the past three years on their trips to China, The Motley Fool researchers have identified companies that are now all up between 100-500% since their recommendations, I hope to do the same.
PART II
There has been much debate recently as to the future of the Chinese economy. Famous hedge fund manager Jim Chanos has publicly come out saying he will short the Chinese economy. While I believe the Chinese real estate market and domestic stock market are overvalued, I think the Chinese companies trading on the U.S. exchanges are screaming buys! Buffett talked about feeling like “an oversexed man in a brothel” in the mid 1970’s because he was so excited about the cheap prices in U.S. stocks, I feel the same about stocks in China right now. No one can predict market fluctuations; I just buy when stocks are trading at a huge discount to their intrinsic value. While I am not sure of the future in the markets in the next year or even two years, I am certain that these companies are exceptional buys for the long term investor.
As I discussed in my previous article, leaders in the pharmaceutical industry have a similar winning business model: a strong nationwide sales and distribution network, strong research and development capabilities and access to capital.
Skystar Biopharmaceuticals appears to be the perfect Buffett-like company. They have a sustainable competitive advantage with little competition in the veterinary health industry. They are currently the only large corporation in this field that is not a state owned enterprise. Skystar also has two important Buffett traits, a high Return on equity and high profit margins of 55% and 42% respectively. This shows that they are not in a heavily competitive industry; profit margins and ROE are low in competitive industries. Skystar has a P/E of 5.96 while it has grown revenue from 6 million in 2005 to 26 million in 2008, and will have substantial revenue growth in fiscal 2009, with estimates between 44-46 million. Skystar also has a strong balance sheet with no long term debt.
Biostar pharmaceuticals is poised for exceptionally strong growth over the next year. They are expanding their sales outlets from 3,512 to 10,000 sales outlets by the end of 2010!! If they reach their estimates, they will have net income growth of at least 100% in fiscal 2009. Biostar’s most important drug, the Xin Aoxing Capsule, used for the treatment of Hepatitis B, has a near monopoly. The drug is the only OTC approved drug of its kind in China, and has 93% efficacy with a cost of pennies on the dollar in comparison to other global competitors. There may be as many as 130 million people in China with hepatitis B, so the target market for this product is huge. They could as much as triple revenues in 2010, and are trading at a p/e of only 8.
Biopharm Asia is involved in the planting, manufacturing, distribution, and retail sale of a large line of health care products. It is trading at a p/e of only 4.42, and grew net income from 5.5 million to 14.4 million from 2007-2008. This company is expanding rapidly and priced as if it was going nowhere, in these situations, it does not make sense not to buy.
Weikang Bio-technology group (WKBT) is another Chinese pharmaceutical company that appears extremely undervalued. They engage in the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine in China. We believe that a lack of investor awareness is one of the primary reasons for this substantial undervaluation.
A valuation comparison of these Chinese companies to their US counterparts is shocking. Pfizer has not grown since 2006, and is trading at a p/e of 13. Walgreens is at a p/e of 16, and has grown revenues from 47 to 63 billion. Sanofi Aventis has had no substantial revenue growth from 2006-2009, yet is trading at a p/e of 14. In China we have companies growing at 30% or greater growth rates, and trading for p/e ratios of less than 8, while in the U.S. we have companies with 0-5% growth rates trading at p/e ratios of 13-16.
The Chinese companies clearly present better value for the intelligent investor. There are a few reasons why this undervaluation happens. Two primary reasons are that these companies are unknown to investors and that they are in China. Investors are afraid of Chinese stocks. They are worried about companies in China because of conflicting opinions about the future of the Chinese economy. This creates an incredible financial opportunity for those who do their research. While I agree that the real estate market and domestic Chinese stock markets are overvalued, many of the Chinese companies trading on US markets or the OTC exchange are extremely undervalued.
Other companies in the Chinese pharmaceutical industry worth watching are CKGT, CSKI, RHGP, and CPHI. This industry is exploding with undervalued companies; investors would be well served to do some serious research.
Zack Buckley
CEO
1. A strong nationwide sales and distribution network
2. Strong research and development capabilities
3. Access to capital in order to expand
While some companies trade with P/E ratios as high as 63, Lotus pharmaceuticals has a P/E of only 5.12. You would expect a low P/E to be indicative of a stalwart company. However, Lotus Pharmaceuticals grew revenues at 59% from 2005-2008 and has net income up 700% since 2005. Lotus Pharmaceuticals revenue streams are a combination of pharmaceuticals wholesaling and the development and sale of proprietary drugs. Their primary growth strategies are expanding their distribution sales channels in order to increase sales, expanding production capacity through the building of a large factory, and bringing new drugs to the market by partnering with top R&D institutions. We believe a company this cheap should not be overlooked. In summary, lotus is a comprehensive company with both strong manufacturing capability and a nationwide distribution network, great R&D capabilities with a new drug pipeline including a Class I drug, and a very attractive valuation.
Vier unterbewertetes chinesisches Pharmas
11. April 2010 | über: JGBO.OB/LTUS.OB/SNBP.OB/TPIS
Durch Platinum Tiger
Während viele US - aufgeführte chinesische kleine Kappen haben bis jetzt dieses Jahr mit einem durchschnittlichen Gewinn des ersten Viertels von 19 Prozent, ein Sektor, pharmazeutische Produkte, ist bestraft worden unnachgiebig von den Investoren geblüht. Die acht pharmazeutischen Aktien verzeichneten in unserem RCS-Index haben verloren in Durchschnitt 25 Prozent ihres Wertes, seit sie am 15. Januar emporragten. Nur ein der acht - nutraceutical Produzent Nutrastar (NUIN.OB) - ist in der positiven Gegend für das Jahr. Mehrere, wie Lotos (LTUS.OB), Sinobiopharma (SNBP.OB) und Tianyin (TPIs) sind unten durch mehr als 20 Prozent und eins, Jiangbo (JGBO.OB), hat verschüttet fast Hälfte seinen Wert in der Vergangenheit drei Monate. Ich glaube, dass mehrere dieser Aktien jetzt tief und der ernsten Investitionsbetrachtung des Verdienstes zu viel verkauft werden.
Mit solch einem sehr großem Leistungsabstand zwischen pharmas und anderen Sektoren, konnte man gereizt werden, um festzustellen, dass die gesamte chinesische Pharmaindustrie schnell Bankrott machendes sein muss. Aber die Wahrheit ist Gesundheitspflege im Allgemeinen, und pharmazeutische Produkte insbesondere, dröhnen. Unveränderliche Regierungsexpansion des Zugangs zu den Gesundheitspflegedienstleistungen und das Verbessern von Patentdurchführung haben in einen schnell wachsenden Markt mit Gewinn aud langfristigen Geschäftengelegenheiten übersetzt. Mit 20 Prozent der Bevölkerung der Welt und des bloßen 2-Prozent-Anteiles des globalen Drogemarktes, ist der Sektor noch in den Anfangsstadien seines Reifezyklus.
So warum hat es soviel baissetendenziösen Druck auf diesen Aktien gegeben? Neue Einkommenansagen sind gemischt worden, und Konkurrenz hat zu Preiskalkulationsdruck für einige Firmen geführt. Aber, während die Industrie fortfährt zu vereinigen, erwarte ich, dass Wettbewerbsdruck nachläßt und viele der Firmen in unserem Index attraktive Erwerbsziele für größere pharmazeutische Spieler darstellen.
Ein Vorrat mit großer möglicher Oberseite ist Jiangbo. Jetzt, handelnd an gut unterhalb des Wertes von seinen $100 Million in den Bargeldbeständen, mit einem Vorwärts-PET von nur ungefähr 2x, ist dieses eine der unterbewertetsten Firmen, die ich gesehen habe. Der Vorrat ist vor kurzem zerschlagen worden und in der Vergangenheit gefallen über 25 Prozent zwei Wochen trotz eines kompletten Fehlens negativen Nachrichten. Die Firma ist ein unveränderlicher Geldhersteller mit festen Aussichten, aber aus Gründen, die zu mir unklar sind, haben Investoren ihn behandelt, als wenn er Erlöschen des Geschäfts ist. Viele vergleichbaren Firmen handeln für 3 bis 5mal soviel wie Jiangbo; es könnte im Preis sich verdoppeln und unterbewertet noch sein.
In Kürze wird Verkaufsdruck zu vermindern gesprungen und kleine Kappe chinesische pharmas drehen sich herum. Ich empfehle mich, Anteile an einigen dieser Aktien für short- zum zyklischen Rückstoß der Halbzeit aufzuheben.
Freigabe: Positionen in JGBO.OB, LTUS.OB
http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen
By Platinum Tiger
While many U.S.-listed Chinese small caps have flourished so far this year with an average first quarter gain of 19 percent, one sector, pharmaceuticals, has been relentlessly punished by investors. The eight pharmaceutical stocks listed in our RCS index have lost on average 25 percent of their value since they peaked on January 15. Only one of the eight - nutraceutical producer Nutrastar (NUIN.OB) - is in positive territory for the year. Several, like Lotus (LTUS.OB), Sinobiopharma (SNBP.OB) and Tianyin (TPI) are down by more than 20 percent, and one, Jiangbo (JGBO.OB), has shed nearly half its value in the past three months. I believe several of these stocks are now deeply oversold and merit serious investment consideration.
With such a huge performance gap between pharmas and other sectors, one might be tempted to conclude that the entire Chinese pharmaceutical industry must be rapidly going bankrupt. But the truth is health care in general, and pharmaceuticals in particular, are booming. Steady government expansion of access to health care services and improving patent enforcement have translated into a rapidly growing market with long-term profit opportunities. With 20 percent of the world's population and a mere 2 percent share of the global drug market, the sector is still in the early stages of its maturity cycle.
So why has there been so much bearish pressure on these stocks? Recent earnings announcements have been mixed, and competition has led to pricing pressure for some companies. But as the industry continues to consolidate, I expect competitive pressures will ease, and many of the companies in our index will present attractive acquisition targets for larger pharmaceutical players.
One stock with great potential upside is Jiangbo. Now trading at well below the value of its $100 million in cash holdings, with a forward PE of only about 2x, this is one of the most undervalued companies I have seen. The stock has been battered recently, dropping over 25 percent in the past two weeks despite a complete absence of negative news. The company is a steady money maker with solid prospects, but for reasons that are unclear to me, investors have treated it as though it's going out of business. Many comparable companies are trading for 3 to 5 times as much as Jiangbo; it could double in price and still be undervalued.
Before long, selling pressure is bound to diminish and small cap Chinese pharmas will turn around. I recommend picking up shares in a few of these stocks for a short- to mid-term cyclical rebound.
Disclosure: Positions in JGBO.OB, LTUS.OB
Endlich gehts Rund ;-))
Lotus Pharmaceuticals' Innovative Drug to Receive SFDA Fast Track Approval
BEIJING, April 20 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its asthma drug Laevo-Bambutero will receive the China's State Food & Drug Administration's (SFDA) Fast Track Approval to enter clinical trials. The SFDA's Drug Review and Evaluation Center told the Company during recent consultations at the end of the Company's IND (Investigative New Drug Application) that formal approval would be granted by the Beijing office of the SFDA.
Laevo-Bambutero has completed the SFDA special review process under Category Two of the four categories of drugs that can receive speedier approval for IND, clinical trials and new drug production. SFDA issues special review and fast-track approval procedures for new drugs in 2009, under the following four categories of drugs:
1) New active pharmaceutical ingredients (APIs) extracted from plants,
animals or minerals, and newly discovered traditional Chinese medicines
(TCM), along with their preparations, and products that are not sold in
the domestic market;
2) Drugs, and their APIs, preparations, and biological products, have not
been approved in the domestic and overseas market;
3) New drugs with superior efficacy for AIDS, malignant tumors and other
rare diseases; and
4) New drugs for diseases for which there is no existing effective
treatment.
CEO, Dr. Zhongyi Liu, commented, "Millions of people are suffering from asthma worldwide, and 30-40 millions of asthma patients are estimated in China. It took ten years to develop Laevo-Bambutero, and we own its patent rights until 2022. We believe it is highly effective and has few side effects. We hope to accelerate the new tablet introduction to market and commercialization."
China's pharmaceutical industry has undergone the transformation from a generic-dominated model to the one that promotes drug innovation. The SFDA's Amended Measures effective in October of 2007 are intended to increase drug safety, tighten appraisal and approval processes while encouraging innovation. Given the SFDA's strict implementation of the Amended Measures, the Company believes that product pipeline pending SFDA approval status should only include Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease, Gliclazide-Controlled Release Tablets for Type 2 diabetes and Laevo-Bambutero for asthma.
About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its other filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.
For more information, please contact:
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.com
http://finance.yahoo.com/news/...prnews-1034024995.html?x=0&.v=59
Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
BEIJING, April 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board:LTUS.ob - News) ("Lotus" or the "Company"), a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC"), today reported it will exhibit at the 63rd PHARMCHINA.
Time: April 24-26, 2010
Venue: International Convention Center, Xiamen
Primary Booth: Liang Fang, Beijing Delegate Area
The Company has attended PHARMCHINA exhibitions every year since 1996 as a way to strengthen customer relationships and attract new distributors, while promoting its products.
Lotus will continue to market both its self-branded and self-produced drugs that have established market shares in China. Lotus will also introduce its upcoming innovative asthma drug Laevo-Bambutero, together with two other pipeline drugs Gliclazide-Controlled Release Tablets for type 2 diabetes and Isosorbide Mononitrate-Sustained Release Tablets for coronary artery disease.
About PHARMCHINA
PHARMCHINA has been the largest and most recognized exhibition in the Chinese pharmaceutical industry over the last thirty years. With a gross floor area of more than 60,000 square meters and leading professional and academic forums, it attracts more than 1,900 exhibitors. PHARMCHINA is a diversified trading and exchange platform for pharmaceutical companies. For more information, please see http://www.pharmchina.com.cn .
About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )
Lotus Pharmaceuticals, Inc. is a growing developer and producer of drugs and a licensed national seller of pharmaceutical items in the PRC. Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular disease, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.
Lotus Pharmaceuticals, Inc.
Yan ZENG, CFO
Tel: +86-10-6389-9868
Email: zy@lotuspharma.comhttp://finance.yahoo.com/news/...-prnews-116943788.html?x=0&.v=95
Laevo-Bambutero completed the SFDA special review process under Category Two of the four categories of drugs that can receive speedier approval: Drugs, and their APIs, preparations, and biological products that have not been approved in the domestic and overseas market.
"Millions of people are suffering from asthma worldwide, and 30-40 million of asthma patients are estimated in China. It took ten years to develop Laevo-Bambutero, and we own its patent rights until 2022. We believe it is highly effective and has few side effects. We hope to accelerate the new tablet introduction to market and commercialization," said Dr. Zhongyi Liu, CEO of Lotus.
The asthma drug joins two other Lotus products that are awaiting SFDA approval: Isosorbide Mononitrate-Sustained Release Tablets for cardiovascular disease, and Gliclazide-Controlled Release Tablets for Type 2 diabetes.
In 2009, Lotus reported revenues actually fell 22% to $57.8 million. On the other hand, net earnings climbed 28% to $16.4 million or 33 cents per share, fully diluted. Net cash provided by operating activities was $31.4 million.
Lotus expressed hope that sales would increase as it began using its new Beijing building complex. It expects EBIT will grow 15-20% in 2010 as direct sale of drugs to third-party pharmacies in Beijing generates additional revenues.
Sanofi-Aventis (NYSE: SNY) has established a regional R&D center in Shanghai (see story) to develop and manage partnerships with China biopharmas. Unlike many of its big pharma competitors, Sanofi-Aventis is not building a lab and hiring scores of scientists to work exclusively on S-A projects. The company says the plan will allow Sanofi-Aventis to take advantage of China’s innovative biopharma culture.
Kun Run Biotechnology (KURU.OB), a biopharma focused on peptide and small molecule drugs, has raised $8 million in a private placement with Caduceus Asia Partners, LP, a fund managed by OrbiMed Advisors, and Mr. Xueyun Cui, who is both Chairman and majority stockholder of Kun Run (see story). In a statement, Mr. Cui said that OrbiMed’s participation would give Kun Run a leg up in its plan to sell products globally.
Artepharm Global Corp. [OTCBB: ARGC] formed a joint venture with a similarly named China company, Artepharm Co. Ltd. (Artepharm China), to market a malaria drug (see story). Artepharm China is a Guangzhou-based biopharma whose malaria drug, Artequick, produced $1.5 million of revenue in 2009. Although Artepharm did not call the transaction a reverse merger, it has most of the characteristics of one.
NeoStem, Inc. (NBS) announced a stem cell collaboration with ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. [OTCBB: IRBS] (see story). NeoStem will investigate whether Homspera, ImmuneRegen’s lead product, will enhance stem cell activity when used in combination with NeoStem's VSEL technology.
Eisai Co., Ltd., the fourth largest Japanese pharma, licensed the China rights to a gastroprokinetic agent, cinitapride tartrate, from Almirall, S.A. of Spain (see story). Eisai obtained exclusive rights to develop, manufacture and market cinitapride in China. Eisai has a production facility in Suzhou. In 2001, Eisai bought the China rights to an antiallergic agent, Kestine, from Almirall. Terms of the new license were not disclosed.
Lotus Pharmaceuticals (LTUS.OB) said the SFDA indicated it would grant fast-track approval to begin clinical trials of its asthma drug Laevo-Bambutero (see story). At a meeting held as part of its Investigative New Drug Application, Lotus was told the Beijing office of the SFDA would issue the approval to begin clinical trials.
Simcere Pharma (NYSE: SCR) reported that diosmectite, the API in its branded generic diarrhea drug Biqi, has passed EU-GMP inspection (see story). Diosmectite is made from a natural mineral, and Simcere owns a high-grade diosmectite mine in China. It is the leading anti-diarrhea drug in China and France.
ATS Medical (NSDQ: ATSI) reported the first commercial implant of the ATS 3f Aortic Bioprosthesis, a tissue valve, was completed recently at Fu Wai Hospital in Beijing, China (see story). ATS Medical, of Plymouth, Minnesota, received SFDA approval of the valve last month. ATS Medical maintains an office in Shanghai. The ATS 3f Aortic Bioprosthesis is a stentless pericardial aortic tissue valve that is designed to function like a native valve.
1
|